Drug Profile


Alternative Names: Betapace AF

Latest Information Update: 05 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berlex Laboratories LLC
  • Developer Bayer HealthCare Pharmaceuticals Inc.
  • Class Antihypertensives; Class III antiarrhythmics; Ethanolamines
  • Mechanism of Action Beta-adrenergic receptor antagonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Atrial fibrillation; Atrial flutter

Most Recent Events

  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
  • 09 Oct 2002 A study has been added to the adverse events and Arrhythmias therapeutic trials sections
  • 03 Jul 2002 A study has been added to the Arrhythmias therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top